Changes in US stocks | Psoriatic drug phase III trial achieved positive results Alumis (ALMS.US) opened and soared by more than 154%

The Zhitong Finance App learned that on Tuesday, the opening of Alumis (ALMS.US) soared by more than 154% to a record high of $20.60. In the news, the company announced positive top-line results from its Envudeucitinib phase III Onward1 and Onward2 clinical trials. Envudeucitinib is a next generation highly selective oral tyrosine kinase 2 (TYK2) inhibitor for patients with moderate to severe plaque psoriasis.

In ONWARD1 and ONWARD2, Envudeucitinib reached all major and secondary endpoints with high statistical significance. In these trials, Envudeucitinib showed better skin clearance (p < 0.0001) compared to placebo at week 16 at the common primary endpoint of psoriasis area and severity index (PASI) 75 and static physician overall assessment (sPGA) 0/1. On average between ONWARD1 and ONWARD2, 74% of patients achieved PASI 75, and 59% of patients achieved spGa 0/1, and the response deepened over time. Furthermore, placebo-adjusted response rates with a common primary endpoint were consistent between the two trials.